Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

Kumar MS, Hancock DC, Molina-Arcas M, Steckel M, East P, Diefenbacher M, Armenteros-Monterroso E, Lassailly F, Matthews N, Nye E, Stamp G, Behrens A, Downward J.

Cell. 2012 Apr 27;149(3):642-55. doi: 10.1016/j.cell.2012.02.059.

2.

GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.

Tessema M, Yingling CM, Snider AM, Do K, Juri DE, Picchi MA, Zhang X, Liu Y, Leng S, Tellez CS, Belinsky SA.

J Thorac Oncol. 2014 Jun;9(6):784-93. doi: 10.1097/JTO.0000000000000165.

3.

Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.

Elsum IA, Yates LL, Pearson HB, Phesse TJ, Long F, O'Donoghue R, Ernst M, Cullinane C, Humbert PO.

Oncogene. 2014 Nov 27;33(48):5523-33. doi: 10.1038/onc.2013.498. Epub 2013 Nov 25.

PMID:
24276238
4.

Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.

Sutterlüty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, Mikulits W, Micksche M, Berger W.

Mol Cancer Res. 2007 May;5(5):509-20.

5.

EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.

Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, Lin SC, Chang YC, Lin SY, Chen SJ, Chen HC, Yeh SD, Wu CW.

Cancer Res. 2010 Nov 1;70(21):8822-31. doi: 10.1158/0008-5472.CAN-10-0638. Epub 2010 Oct 26.

6.

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne PH, Kuznetsov H, Kelly G, Saunders B, Howell M, Downward J, Hancock DC.

Cell Res. 2012 Aug;22(8):1227-45. doi: 10.1038/cr.2012.82. Epub 2012 May 22.

7.

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.

Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD.

Mol Cancer Ther. 2011 Feb;10(2):336-46. doi: 10.1158/1535-7163.MCT-10-0750.

8.

MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.

Patel A, Burton DG, Halvorsen K, Balkan W, Reiner T, Perez-Stable C, Cohen A, Munoz A, Giribaldi MG, Singh S, Robbins DJ, Nguyen DM, Rai P.

Oncogene. 2015 May 14;34(20):2586-96. doi: 10.1038/onc.2014.195. Epub 2014 Jul 14.

9.

Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients.

Kameyama K, Huang CL, Liu D, Masuya D, Nakashima T, Sumitomo S, Takami Y, Kinoshita M, Yokomise H.

Clin Cancer Res. 2003 Oct 15;9(13):4926-34.

10.

Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.

Guin S, Ru Y, Wynes MW, Mishra R, Lu X, Owens C, Barn AE, Vasu VT, Hirsch FR, Kern JA, Theodorescu D.

J Thorac Oncol. 2013 Dec;8(12):1492-501. doi: 10.1097/JTO.0000000000000007.

11.

Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.

Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K.

Cancer Res. 2009 Aug 15;69(16):6515-21. doi: 10.1158/0008-5472.CAN-09-1076. Epub 2009 Jul 28.

12.

The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients.

Kim YC, Park KO, Kern JA, Park CS, Lim SC, Jang AS, Yang JB.

Lung Cancer. 1998 Dec;22(3):181-90.

PMID:
10048471
13.

KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.

Moran DM, Trusk PB, Pry K, Paz K, Sidransky D, Bacus SS.

Mol Cancer Ther. 2014 Jun;13(6):1611-24. doi: 10.1158/1535-7163.MCT-13-0649. Epub 2014 Mar 31.

14.

Krüppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells.

Ito G, Uchiyama M, Kondo M, Mori S, Usami N, Maeda O, Kawabe T, Hasegawa Y, Shimokata K, Sekido Y.

Cancer Res. 2004 Jun 1;64(11):3838-43.

15.

The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.

Kanou T, Oneyama C, Kawahara K, Okimura A, Ohta M, Ikeda N, Shintani Y, Okumura M, Okada M.

Mol Cancer Res. 2011 Jan;9(1):103-14. doi: 10.1158/1541-7786.MCR-10-0340. Epub 2010 Dec 14.

16.

Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

Balbin OA, Prensner JR, Sahu A, Yocum A, Shankar S, Malik R, Fermin D, Dhanasekaran SM, Chandler B, Thomas D, Beer DG, Cao X, Nesvizhskii AI, Chinnaiyan AM.

Nat Commun. 2013;4:2617. doi: 10.1038/ncomms3617.

17.

Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.

Vandal G, Geiling B, Dankort D.

PLoS One. 2014 Jan 28;9(1):e84745. doi: 10.1371/journal.pone.0084745. eCollection 2014.

18.

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK.

Clin Cancer Res. 2013 Nov 15;19(22):6183-92. doi: 10.1158/1078-0432.CCR-12-3904. Epub 2013 Sep 17.

19.

Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.

Vicent S, Chen R, Sayles LC, Lin C, Walker RG, Gillespie AK, Subramanian A, Hinkle G, Yang X, Saif S, Root DE, Huff V, Hahn WC, Sweet-Cordero EA.

J Clin Invest. 2010 Nov;120(11):3940-52. doi: 10.1172/JCI44165. Epub 2010 Oct 25.

20.

Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.

Mortazavi F, Lu J, Phan R, Lewis M, Trinidad K, Aljilani A, Pezeshkpour G, Tamanoi F.

BMC Cancer. 2015 May 9;15:381. doi: 10.1186/s12885-015-1360-4.

Supplemental Content

Support Center